Comparative Financial Performance Analysis of Turkish and Global Pharmaceutical Companies with MCDM Methods
Journal of Business and Trade · 29.06.2026 · 7 (1) · 16-35
DOI: 10.58767/joinbat.1959292 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Business and Trade, online erschienen am 29.06.2026. Verfasst von Zafer Özdil und 1 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
In this study, using the financial data of 12 Turkish and global pharmaceutical companies for the period 2021–2025 and the most commonly used financial performance metrics in the literature, the weights of these metrics were first calculated using the LOPCOW and MEREC methods. Once the metric weights had been determined, the companies’ financial performance was analysed using the EDAS and CoCoSo methods. The results of the performance analysis were evaluated comparatively. When selecting companies for the study, care was taken to include firms from developed countries, emerging markets, manufacturers, distributors, and biotechnology-focused firms. In selecting the criteria to determine the companies’ financial performance, those deemed critical for the pharmaceutical sector were chosen. For the selection of the analysis period, the post-pandemic transformation and the use of current data were chosen. According to the joint weighting results obtained using the LOPCOW and MEREC methods, the most important criterion was identified as C1 (Return on Assets (ROA)) in 2021, C5 (Debt to Equity Ratio (D/E)) in 2022, C1 (Return on Assets (ROA)) in 2023, and C4 (Current Ratio (CR)), and C4 (Current Ratio (CR)) in 2025. According to the EDAS and CoCoSo methods, AstraZeneca and Selçuk Ecza Deposu were found to have the poorest financial performance in the 2021–2025 ranking. Conversely, according to the EDAS and CoCoSo methods, Roche and EIS Eczacıbaşı İlaç were found to have demonstrated the best performance in the financial performance ranking for the period 2021–2025
Zitieren
APA
Özdil, Z., & Özdil, S. (2026). Comparative Financial Performance Analysis of Turkish and Global Pharmaceutical Companies with MCDM Methods. Journal of Business and Trade, 7(1), 16-35. https://doi.org/10.58767/joinbat.1959292
Vancouver
Özdil Z, Özdil S. Comparative Financial Performance Analysis of Turkish and Global Pharmaceutical Companies with MCDM Methods. Journal of Business and Trade. 2026;7(1):16-35. doi:10.58767/joinbat.1959292
BibTeX
@article{zdil2026,
author = {Özdil, Zafer and Özdil, Sudenaz},
title = {Comparative Financial Performance Analysis of Turkish and Global Pharmaceutical Companies with MCDM Methods},
journal = {Journal of Business and Trade},
year = {2026},
volume = {7},
number = {1},
pages = {16--35},
doi = {10.58767/joinbat.1959292}
}
EUVIMED